Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management

Critical Care Medicine

Volumn 34, Issue 12, 2006, Pages 2898-2911

  Napolitano, Lena M ^a   Warkentin, Theodore E ^b   AlMahameed, Amjad ^c   Nasraway, Stanley A ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b HAMILTON REGIONAL LABORATORY MEDICINE PROGRAM   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Critical care; Heparin; Heparin induced thrombocytopenia; Intensive care unit; Thrombocytopenia

Indexed keywords

ANCROD; ANTIBODY; ARGATROBAN; COUMARIN; DANAPAROID; DEXTRAN 40; HEPARIN; HEPARINOID; LEPIRUDIN; THROMBIN INHIBITOR; WARFARIN;

ANAPHYLAXIS; BLEEDING; CHILL; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSPNEA; EARLY DIAGNOSIS; FEVER; HEART ARREST; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HOT FLUSH; HUMAN; HYPERTENSION; INTENSIVE CARE; LABORATORY TEST; NAUSEA; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; RESPIRATORY ARREST; REVIEW; RISK REDUCTION; TACHYCARDIA; THORAX PAIN; THROMBOCYTE COUNT; THROMBOEMBOLISM; THROMBOSIS; TRANSIENT GLOBAL AMNESIA; VOMITING;

EID: 33751310773     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000248723.18068.90     Document Type: Article

References (101)

1. Baughman RP, Lower EE, Flessa HC, et al: Thrombocytopenia in the intensive care unit. Chest 1993; 104:1243-1247
2. Hanes SD, Quarles DA, Boucher BA: Incidence and risk factors of thrombocytopenia in critically ill trauma patients. Ann Pharmacother 1997; 31:285-289
3. Stéphan F, Hollande J, Richard O, et al: Thrombocytopenia in a surgical intensive care unit: Incidence, risk factors and outcome. Chest 1999; 115:1363-1370
4. Marshall JC, Cook DJ, Christou NV, et al: Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638-1652
5. Strauss R, Wehler M, Mehler K, et al: Thrombocytopenia in patients in the medical intensive care unit: Bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30:1765-1771
6. Cawley MJ, Wittbrodt ET, Boyce EG, et al: Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy 1999; 19:108-113
7. Akca S, Haji-Michael P, de Mendonca A, et al: Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30:753-756
8. Vanderschueren S, De Weerdt A, Malbrain M, et al: Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28:1871-1876
9. Drews RE: Critical issues in hematology: Anemia, thrombocytopenia, coagulopathy and blood product transfusions in critically ill patients. Clin Chest Med 2003; 24:607-622
10. Warkentin TE, Chong BH, Greinacher A: Heparin-induced thrombocytopenia: Towards consensus. Thromb Haemost 1998; 79:1-7
11. Greinacher A, Janssens U, Berg G, et al: Heparin-associated thrombocytopenia Study (HAT) Investigators. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100:587-593
12. Warkentin TE, Kelton JG: A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996; 101:502-507
13. Brieger DB, Mak K-H, Kottke-Marchant K, et al: Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31:1449-1459
14. Nand S, Wong W, Yuen B, et al: Heparin-induced thrombocytopenia with thrombosis: Incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997; 56:12-16
15. Warkentin TE, Hayward CPM, Boshkov LK, et al: Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994; 84:3691-3699
16. Warkentin TE, Sheppard JI: Generation of platelet-derived microparticles and procoagulant activity by heparin-induced thrombocytopenia IgG/serum and other IgG platelet agonists: A comparison with standard platelet agonists. Platelets 1999; 10:319-326
17. Warkentin TE: Heparin-induced thrombocytopenia: Diagnosis and management. Circulation 2004; 110:e454-e458
18. Visentin GP, Ford SE, Scott JP, et al: Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93:81-88
19. Pouplard C, Lochmann S, Renard B, et al: Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97:3300-3302
20. Warkentin TE, Kelton JG: Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344:1286-1292
21. Warkentin TE, Levine MN, Hirsh J et al: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330-1335
22. Warkentin TE, Sheppard JI, Horsewood P, et al: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708
23. Lee DP, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. 3rd ed. Warkentin TE, Greinacher A (Eds). New York, Marcel Dekker, 2004, pp 107-148
24. Bell WR, Royall RM: Heparin-associated thrombocytopenia: A comparison of three heparin preparations. N Engl J Med 1980; 303:902-907
25. Warkentin TE, Roberts RS, Hirsh J, et al: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
26. Girolami B, Prandoni P, Stefani PM, et al: The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: A prospective cohort study. Blood 2003; 101:2955-2959
27. Warkentin TE, Barkin RL: Newer strategies for the treatment of heparin-induced thrombocytopenia. Pharmacotherapy 1999; 19:181-195
28. Warkentin TE, Kelton JG: Heparin and platelets. Hematol Oncol Clin North Am 1990; 4:243-264
29. Verma AK, Levine M, Shalansky SJ, et al: Frequency of heparin-induced thrombocytopenia in critical care patients. Pharmacotherapy 2003; 23:745-753
30. Crowther MA, Cook DJ, Meade MO, et al: Thrombocytopenia in medical-surgical critically ill patients: Prevalence, incidence and risk factors. J Crit Care 2005; 20:348-353
31. Cook DJ, Crowther M, Meade M, et al: VTE in the ICU Workshop Participants: Prevalence, incidence and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J Crit Care 2005; 20:309-313
32. Hourigan LA, Walters DL, Keck SA, et al: Heparin-induced thrombocytopenia: A common complication in cardiac transplant recipients. J Heart Lung Transplant 2002; 21:1283-1289
33. Schmugge M, Risch L, Huber AR, et al: Heparin-induced thrombocytopenia-associated thrombosis in pediatric intensive care patients. Pediatrics 2002; 109:E10
34. Hoh BL, Aghi M, Pryor JC, et al: Heparin-induced thrombocytopenia type II in subarachnoid hemorrhage patients: Incidence and complications. Neurosurgery 2005; 57:243-248
35. Ohman EM, Granger CB, Rice L, et al: Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: A registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. J Thromb Thrombolysis 2005; 19:11-19
36. Hirsh J, Heddle N, Kelton JG: Treatment of heparin-induced thrombocytopenia. A critical review. Arch Intern Med 2004; 164:361-369
37. Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia. Arch Pathol Lab Med 2002; 126:1415-1423
38. Hong AP, Cook DJ, Sigouin CS, et al: Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 2003; 101:3049-3051
39. Warkentin TE, Elavathil LJ, Hayward CPM, et al: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann Intern Med 1997; 127:804-812
40. Warkentin TE: Clinical picture of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. 3rd ed. Warkentin TE, Greinacher A (Eds). New York, Marcel Dekker, 2004, pp 53-106
41. Warkentin TE: Heparin-induced thrombocytopenia and vascular surgery. Acta Chir Belg 2004; 104:257-65
42. LaMonte MP, Brown PM, Hursting MJ: Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32:976-980
43. Greinacher A, Farner B, Kroll H, et al: Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost 2005; 94:132-135
44. Wester JP, Haas FJ, Biesma DH, et al: Thrombosis and hemorrhage in heparin-induced thrombocytopenia in seriously ill patients. Intensive Care Med 2004; 30:1927-1934
45. Fabris F, Ahmad S, Cella G, et al: Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications - A review. Arch Pathol Lab Med 2000; 124:1657-1666
46. Warkentin TE: Clinical picture of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. 3rd ed. Warkentin TE, Greinacher A (Eds). New York, Marcel Dekker, 2004, pp 53-106
47. Warkentin TE, Aird WC, Rand JH: Platelet-endothelial interactions: Sepsis, HIT, and antiphospholipid syndrome. Hematology (Am Soc Hematol Educ Program) 2003; 497-519
48. Lo GK, Juhl D, Warkentin TE, et al: Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thrombo Haemost 2006; 4:894-896
49. Mims MP, Manian P, Rice L: Acute cardiorespiratory collapse from heparin: A consequence of heparin-induced thrombocytopenia. Eur J Haematol 2004; 72:366-369
50. Warkentin TE: Heparin-induced skin lesions. Br J Haematol 1996; 92:494-497
51. Warkentin TE, Roberts RS, Hirsh J, et al: Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: A nested cohort study. Chest 2005; 127:1857-1861
52. Warkentin TE: Heparin-induced thrombocytopenia, Part 1: The diagnostic clues. J Crit Illness 2002; 17:172-178
53. Warkentin TE, Roberts RS, Hirsh J, et al: An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003; 163:2518-2524
54. Lubenow N, Kempf R, Eichner A, et al: Heparin-induced thrombocytopenia. Temporal pattern of thrombocytopenia in relation to initial use or re-exposure to heparin. Chest 2002; 122:37-42
55. Warkentin TE: Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol 1998; 35(Suppl 5):S9-S16
56. Warkentin TE: Clinical picture of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. 3rd ed. Warkentin TE, Greinacher A (Eds). New York, Marcel Dekker, 2004, pp 53-106
57. Rice L, Attisha WK, Drexler A, et al: Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med 2002; 136:210-215
58. Warkentin TE, Kelton JG: Delayed-onset heparin-induced thrombocytopenia and thrombosis. Ann Intern Med 2001; 135:502-506
59. Warkentin TE, Bernstein RA: Delayed-onset heparin-induced thrombocytopenia and cerebral thrombosis after a single administration of unfractionated heparin. N Engl J Med 2003; 348:1067-1069
60. Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: Recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl):311S-337S
61. Bailey RT Jr, Ursick JA, Heim KL, et al: Heparin-associated thrombocytopenia: A prospective comparison of bovine lung heparin, manufactured by a new process, and porcine intestinal heparin. Drug Intell Clin Pharm 1986; 20:374-378
62. Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2:148-157
63. Walenga JM, Bick RL: Heparin-induced thrombocytopenia, paradoxical thromboembolic effects of heparin therapy. Med Clin North Am 1998; 82:635-659
64. Warkentin TE, Sheppard JI, Horsewood P, et al: Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96:1703-1708
65. Warkentin TE: Platelet count monitoring and laboratory testing for heparin-induced thrombocytopenia: Recommendations of the College of American Pathologists. Arch Pathol Lab Med 2002; 126:1415-1423
66. Dager WE, White RH: Pharmacotherapy of heparin-induced thrombocytopenia. Expert Opin Pharmacother 2003; 4:919-940
67. Bauer TL, Arepally G, Konkle BA, et al: Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation 1997; 95:1242-1246
68. Trossaert M, Gaillard A, Commin PL, et al: High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101:653-655
69. Visentin GP, Malik M, Cyganiak KA, et al: Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin: platelet factor 4 complexes. J Lab Clin Med 1996; 128:376-383
70. Warkentin TE, Heddle NM: Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep 2003; 2:148-157
71. Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest 2005; 127(2 Suppl):35S-45S
72. Zwicker JI, Uhl L, Huang WY, et al: Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004; 2:2133-2137
73. Chong BH, Gallus AS, Cade JF, et al: Australian HIT Study Group: Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study. Thromb Haemost 2001; 86:1170-1175
74. Lubenow N, Warkentin TE, Greinacher A, et al: Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. Thromb Res 2006; 117:507-515
75. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119(Suppl 1):64S-94S
76. DiNisio M, Middledorp S, Buller HR: Direct thrombin inhibitors (drug therapy). N Engl J Med 2005; 353:1028-1040
77. Williamson DR, Boulanger I, Tardif M, et al: Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004; 24:409-414
78. Lewis BE, Wallis DE, Berkowitz SD, et al: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103:1838-1843
79. Lewis BE, Wallis DE, Leya F, et al: Argatroban anticoagulant in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003; 163:1849-1856
80. Huhle G, Hoffmann U, Song X, et al: Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999; 106:195-201
81. Eichler P, Friesen HJ, Lubenow N, et al: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000; 96:2373-2378
82. Badger NO, Butler K, Hallman LC: Excessive anticoagulation and anaphylactic reaction after rechallenge with lepirudin in a patient with heparin-induced thrombocytopenia. Pharmacotherapy 2004; 24:1800-1803
83. Greinacher A, Lubenow N, Eichler P: Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003; 108:2062-2065
84. Greinacher A, Volpel H, Janssens U, et al: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study. Circulation 1999; 99:73-80
85. Bartholomew JR: Transition to oral anticoagulant in patients with heparin-induced thrombocytopenia. Chest 2005; 127(2 Suppl):27S-34S
86. Warkentin TE: Bivalent direct thrombin inhibitors: Hirudin and bivalirudin. Best Pract Res Clin Haematol 2004; 17:105-125
87. Stephens JL, Koerber JM, Mattson JC, et al: Effect of lepirudin on the international normalized ratio. Ann Pharmacother 2005; 39:28-31
88. Gosselin RC, King JH, Janatpur KA, et al: Effects of pentasaccharide (fondaparinux) and direct thrombin inhibitors on coagulation testing. Arch Pathol Lab Med 2004; 128:1142-1145
89. Greinacher A, Eichler P, Lubenow N, et al: Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96:846-851
90. Hirsch J, Anand SS, Halperin JL, et al: Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001; 103:2994-3018
91. Wallis DE, Workman DL, Lewis BE, et al: Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999; 106:629-635
92. Lubenow N, Eichler P, Lietz T, et al: Lepirudin in patients with heparin-induced thrombocytopenia - Results of the third prospective study (HAT3) and a combined analysis of HAT-1, HAT-2, and HAT3. J Thromb Haemost 2005; 3:2428-2436
93. Lubenow N, Eichler P, Lietz T, et al: Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: An analysis of 3 prospective studies. Blood 2004; 104:3072-3077
94. Lubenow N, Eichler P, Greinacher A: Results of a large drug-monitoring program confirm the safety and efficacy of lepirudin in patients with immune-mediated heparin-induced thrombocytopenia (HIT). Blood 2002; 100:502a
95. Tuncali BE, Kuvaki B, Tuncali B, et al: A comparison of the efficacy of heparinized and nonheparinized solutions for maintenance of perioperative radial arterial catheter patency and subsequent occlusion. Anesth Analg 2005; 100:1117-1121
96. American Association of Critical Care Nurses. Evaluation of the effects of heparinized and nonheparinized flush solutions on the patency of arterial pressure monitoring lines: The AACN Thunder Project. Am J Crit Care 1993; 2:3-15
97. Agharazii M, Plamondon I, Lebel M, et al: Estimation of heparin leak into the systemic circulation after central venous heparin lock. Nephrol Dial Transplant 2005; 20:1238-1240
98. McGill RL, Blas A, Bialkin S, et al: Clinical consequences of heparin-free hemodialysis. Hemodial Int 2005; 9:393-398
99. Nasuno A, Matsubara T, Hori T et al: Acute pulmonary thromboembolism induced by prophylactic heparin use and a heparin-coated catheter: A case of heparin-induced thrombocytopenia and thrombosis syndrome. Circ J 2003; 67:96-98
100. Cruz D, Karlsberg R, Takano Y, et al: Subacute stent thrombosis associated with a heparin-coated stent and heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2003; 58:80-83
101. Laster J, Silver D: Heparin-coated catheters and heparin-induced thrombocytopenia. J Vasc Surg 1988; 7:667-672